Prostate Cancer Treatments
There are numerous treatments for localized prostate cancer and each has its own benefits and drawbacks. Patients and their physicians must weigh many factors when determining the best treatment option. Age, Gleason score (measures aggressiveness), PSA, lifestyle and quality of life all may be factors in the equation of finding the optimal treatment. Treatments available include:
- High Intensity Focused Ultrasound (HIFU)
- Radical prostatectomy
- Radiation therapy
- Hormone therapy
- Cryotherapy
Some patients are choosing no treatment at all, called watchful waiting or active surveillance, because of the effects on quality of life after treatment. The treatment modalities are described below in more detail.
IMPORTANT INFORMATION: HIFU with the Sonablate® 500 is not approved for use in the U.S. The Sonablate® 500 remains investigational in the U.S. and is being studied for the treatment of prostate cancer in clinical trials in the U.S. FDA has made no decision as to the safety or efficacy of the Sonablate® 500 for the treatment of prostate cancer. The information below is provided for general information purposes only and is not intended to replace sound professional medical advice and care. All treatment options and potential outcomes and complications should be discussed with a qualified health care provider.
High Intensity Focused Ultrasound
HIFU with the Sonablate 500 is a minimally invasive treatment option for prostate cancer that uses a transrectal probe to focus ultrasound waves in the prostate. At a very precise and targeted location, the temperature is rapidly elevated which causes tissue destruction. During HIFU, typically the entire prostate is treated or ablated. In most cases, HIFU with the Sonablate 500 takes between two to four hours and is performed as an out-patient procedure. A catheter is inserted during the procedure that is worn for one to four weeks. People usually are up and walking around within hours after HIFU and can return to a normal lifestyle within a couple of days. After the procedure, some HIFU patients experience frequency, urgency, mild discomfort or discharge in urinary stream. Studies performed outside the US report that potential side effects may also include urinary stricture, retention, incontinence, erectile dysfunction and rectal fistula.
Radical Prostatectomy
A radical prostatectomy is surgery to remove the entire prostate gland and some of the tissue around it and may be done by open or laparoscopic surgery. The advantages of a radical prostatectomy include complete removal of the prostate and a long history of use. An open prostatectomy may take two to four hours, and a laparoscopic prostatectomy may take up to eight hours. The procedure is usually performed under general anesthesia and requires a hospital stay and catherization.
Radiation Therapy
There are two primary types of radiation therapy: External Beam Radiation Therapy (“EBRT”) and brachytherapy or seed implants. EBRT is usually recommended for men with a prostate volume less than 60 grams and involves several weeks of radiation directed at the cancer from outside of the body. Brachytherapy is radiation therapy transmitted by tiny radioactive pellets placed inside the prostate.
Hormone Therapy
Hormone therapy, also known as androgen deprivation therapy or androgen suppression therapy aims to reduce the levels of male hormones, such as testosterone, in the body. Lowering these hormone levels can shrink prostate cancer tumors or slow the growth. However, hormone therapy is a palliative treatment and does not cure prostate cancer, and carries a risk of side effects such as decreased mental acuity, fatigue, weight gain, depression, anemia, osteoporosis, anemia and loss of muscle mass.
Cryotherapy
Cryotherapy, also known as cryosurgery or cryoablation, is a minimally invasive procedure that involves freezing the cells in the prostate to bring about destruction or elimination. Cold gases are passed through needles that are placed in the prostate, creating ice balls that destroy the gland. The procedure is ultrasound guided by a physician and is usually performed under spinal, epidural, or general anesthesia. Side effects from cryotherapy may include swelling, erectile dysfunction, incontinence and rectal fistula. Again, the information is provided for general information purposes only and is not intended to replace sound professional medical advice and care. All treatment options, potential outcomes and complications should be discussed with a qualified health care provider. Prostate Cancer Treatment Comparison Chart

General references
Thompson I, Thrasher JB, Aus G et al. Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update. J Urol 177:2106-2131, 2007
Prostate Cancer Treatment Guide http://www.prostate-cancer.com/
Prostate Cancer Treatments, Prostate Cancer Institute Online http://www.prostate-cancer-institute.org/prostate-cancer-treatment/prostate-cancer-treatment.html
HIFU
Uchida T, Ohkusa H, Yamashita H et al. Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Intl J Urol 13:228-233, 2006
Uchida T, Ohkusa H, Nagata Y et al. Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int 97:56-61, 2005
Cryosurgery
Cooperberg M, Carroll P, Shinohara K. Prostate Cancer: Cryotherapy. http://www.emedicine.com/med/TOPIC3539.HTM
Mouraviev V and Polascik TJ. Update on cryotherapy for prostate cancer in 2006. Current Opinion Urol 16:152-156, 2006
Bahn DK, Lee F, Badalament R et al. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 60 (Suppl 2A):3-11, 2002
Han KR, Cohen JK, Miller RJ et al. Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol 170:1126-1130, 2003
Long JP, Bahn D, Lee F et al. Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology 57:518-523
Lam JS, Shvarts O and Belldegrun AS. Cryotherapy for PCa: the next generation. Contemporary Urol 16:2-12, 2004
Radical Prostatectomy
Han M, Partin AW, Zahurak M et al.: Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169: 517-523, 2003
Madalinska JB, Essink-Bot M-L, de Koning HJ et al. Health-related Quality-of-Life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 19:1619-1628, 2001.
Potosky AL, Davis WW, Hoffman RM et al.: Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 96(18):1358-1367, 2004
Roehl KA, Han M, Ramos CG et al.: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172:910-914, 2004
Ung JO, Richie JP, Chen M-H et al.: Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 60:458-463, 2002
Catalona WJ, Basler JW: Return of erections and urinary continence following nerve sparing radical retropubic prostatectomy. J Urol 150 (3): 905-7, 1993.
External Beam Radiation Therapy
Madalinska JB, Essink-Bot M-L, de Koning HJ et al. Health-related Quality-of-Life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 19:1619-1628, 2001.
Potosky AL, Legler J, Albertsen PC et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 92:1582-1592, 2000.
Rosser CJ, Chichakli R, Levy LB et al. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with external beam radiation. J Urol 168:536-541, 2002.
Zietman AL, Chung CS, Cohen JJ et al. 10-Year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study. J Urol 171:210-214, 2004.
Brachytherapy
Grimm PD, Blasko JC, Sylvester JE et al. 10-Year biochemical (prostate-specific antigen) control of prostate cancer with 125I brachytherapy. Int J Radiation Oncology Biol Phys 51:31-40.
Potters L, Morgenstern C, Calugaru E et al. 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173:1562-1566, 2005
Talcott JA, Clark JA, Stark PC et al. Long-term treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treated. J Urol 166:494-499, 2001
|